Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Connecticut biotech gets $150M for Phase 3 trials of oral Rogaine

Summary by endpoints.news
Veradermics has raised the week's second megaround for a hair loss biotech, collecting a $150 million Series C from prominent life sciences investors. The New Haven, CT-based biotech plans to use the funding to get ...
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

endpoints.newsendpoints.news

Connecticut biotech gets $150M for Phase 3 trials of oral Rogaine

Veradermics has raised the week's second megaround for a hair loss biotech, collecting a $150 million Series C from prominent life sciences investors. The New Haven, CT-based biotech plans to use the funding to get ...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

endpoints.news broke the news in on Thursday, October 16, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

New Haven, Connecticut icon

New Haven, Connecticut

News
For You
SearchBlindspotLocal